What is it about?
A new class of anti-diabetic medicine, SGLT2 inhibitors, are attracting world-wide attention for its kidney and heart protective effects.
Featured Image
Why is it important?
SGLT2 inhibitors were initially developed as a diabetic medicine, but they may also be useful for non-diabetic kidney diseases.
Read the Original
This page is a summary of: The Rationale and Evidence for SGLT2 Inhibitors as a Treatment for Nondiabetic Glomerular Disease, Glomerular Diseases, January 2021, Karger Publishers,
DOI: 10.1159/000513659.
You can read the full text:
Contributors
The following have contributed to this page
